Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A PEREZ

Showing results (21-30 of 3,483) with videos related to

Pageof 349
Sort By:
Clinical Breast Cancer|September 10, 2008
Cardiac toxicity of ErbB2-targeted therapies: what do we know?Edith A Perez
Seminars in Oncology|June 30, 2007
Novel enhanced delivery taxanes: an updateEdith A Perez
The Oncologist|November 18, 2006
Appraising adjuvant aromatase inhibitor therapyEdith A Perez
Radiology|August 1, 1995
Carcinoma of the prostate: a model for management under impending health care system reform. 1994 RSNA annual oration in radiation oncologyC A Perez
Clinical Therapeutics|July 1, 1996
Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesisE A Perez
The Oncologist|February 1, 2011
Breast cancer management: opportunities and barriers to an individualized approachEdith A Perez
Cancer Journal (Sudbury, Mass.)|January 27, 2004
Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunitiesCarlos A Perez
Rays|December 18, 2004
Dose fractionation and biological optimization in carcinoma of the uterine cervixCarlos A Perez
Current Oncology Reports|December 21, 2002
Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?Edith A Perez
Journal of Substance Abuse Treatment|May 1, 1993
The ambulatory treatment of noncompulsive users of psychoactive substancesA Perez-Gomez
Pageof 349

Showing results (21-30 of 3,483) with videos related to

Sort By:
Pageof 349
Clinical Breast Cancer|September 10, 2008
Cardiac toxicity of ErbB2-targeted therapies: what do we know?Edith A Perez
Seminars in Oncology|June 30, 2007
Novel enhanced delivery taxanes: an updateEdith A Perez
The Oncologist|November 18, 2006
Appraising adjuvant aromatase inhibitor therapyEdith A Perez
Radiology|August 1, 1995
Carcinoma of the prostate: a model for management under impending health care system reform. 1994 RSNA annual oration in radiation oncologyC A Perez
Clinical Therapeutics|July 1, 1996
Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesisE A Perez
The Oncologist|February 1, 2011
Breast cancer management: opportunities and barriers to an individualized approachEdith A Perez
Cancer Journal (Sudbury, Mass.)|January 27, 2004
Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunitiesCarlos A Perez
Rays|December 18, 2004
Dose fractionation and biological optimization in carcinoma of the uterine cervixCarlos A Perez
Current Oncology Reports|December 21, 2002
Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?Edith A Perez
Journal of Substance Abuse Treatment|May 1, 1993
The ambulatory treatment of noncompulsive users of psychoactive substancesA Perez-Gomez
Pageof 349